Pharmacology News

Opioid-associated ototoxicity, or hearing loss, appears to be an adverse event that can occur with the use of a variety of opioids, according to research published in the Journal of Medical Toxicology.

Galcanezumab was more effective than placebo in preventing migraine among patients with treatment-resistant migraine who also had other pain disorders, according to research presented at this year’s virtual PAINWeek.

Medicare Part D list prices in 2019 for the new, “novel” generation of second-line drugs for glycemic control sometimes cost hundreds of dollars more than the older “traditional” formulations of drugs, according to researchers.

There is no strong evidence to date to support or discourage the use of NSAIDs in patients with COVID-19, according to a presentation during the virtual PAINWeek meeting.

Older adults who received fluoroquinolones had a low risk for aortic aneurysm or aortic dissection, two studies published in JAMA Internal Medicine show.

Third-party and out-of-pocket payments for a 30-day supply of Truvada for HIV pre-exposure prophylaxis added up to $2.08 billion in 2018, data show.

Honey may be more effective than usual care for symptoms of upper respiratory tract infection, or URTI, according to research published in BMJ Evidence-Based Medicine.

CDC data show that primary care prescribers were responsible for more than half of hydroxychloroquine and chloroquine prescriptions dispensed at outpatient retail pharmacies between March and April in the United States.

In this video, Raman K. Malhotra, MD, FAASM, neurologist and sleep specialist at Washington University, discusses “exciting findings” on treatments for narcolepsy, obstructive sleep apnea and insomnia that were presented at the virtual SLEEP 2020 meeting.

States and tribes will receive nearly $3 billion over the next 2 years for prevention, treatment and recovery support services for people with opioid use disorders, according to a press release from HHS.